• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
SARS-CoV: Lessons learned; opportunities missed for SARS-CoV-2.SARS-CoV:吸取的教训;错失的针对 SARS-CoV-2 的机会。
Rev Med Virol. 2021 Jan;31(1):1-6. doi: 10.1002/rmv.2152. Epub 2020 Aug 18.
2
SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.严重急性呼吸综合征(SARS)、中东呼吸综合征(MERS)和严重急性呼吸综合征冠状病毒 2(COVID-19)治疗:专利述评。
Expert Opin Ther Pat. 2020 Aug;30(8):567-579. doi: 10.1080/13543776.2020.1772231. Epub 2020 Jun 7.
3
[Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].[2019冠状病毒病及严重急性呼吸综合征冠状病毒2的诊断、治疗、控制与预防:回归未来]
Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):571-592. doi: 10.13345/j.cjb.200115.
4
Remdesivir against COVID-19 and Other Viral Diseases.瑞德西韦治疗 COVID-19 及其他病毒性疾病。
Clin Microbiol Rev. 2020 Oct 14;34(1). doi: 10.1128/CMR.00162-20. Print 2020 Dec 16.
5
Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.阐明 COVID-19 及其类似物 SARS 和 MERS 的药物再利用谱。
Mini Rev Med Chem. 2021;21(20):3191-3202. doi: 10.2174/1389557521666210225114733.
6
The Potential of Glycyrrhizinate in the Management of COVID-19: A Systematic Review of the Efficacy and Safety of Glycyrrhizin Preparations in the Treatment of SARS and MERS.甘草酸在 COVID-19 管理中的潜力:甘草甜素制剂在治疗 SARS 和 MERS 中的疗效和安全性的系统评价。
Am J Chin Med. 2020;48(7):1539-1552. doi: 10.1142/S0192415X20500767. Epub 2020 Nov 13.
7
A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.洛匹那韦疗法治疗严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒的系统评价——为新型冠状病毒病治疗方案提供参考。
J Med Virol. 2020 Jun;92(6):556-563. doi: 10.1002/jmv.25729. Epub 2020 Mar 12.
8
Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.新型冠状病毒肺炎、严重急性呼吸综合征和中东呼吸综合征的生物学、临床和流行病学特征,以及 ACE2 的 AutoDock 模拟
Infect Dis Poverty. 2020 Jul 20;9(1):99. doi: 10.1186/s40249-020-00691-6.
9
Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.利用天然化合物靶向 SARS-CoV-2 感染的药物发现的当前方法。
Virus Res. 2020 Dec;290:198169. doi: 10.1016/j.virusres.2020.198169. Epub 2020 Sep 24.
10
The emergence of a novel coronavirus (SARS-CoV-2) disease and their neuroinvasive propensity may affect in COVID-19 patients.新型冠状病毒(SARS-CoV-2)疾病的出现及其神经侵袭倾向可能会影响 COVID-19 患者。
J Med Virol. 2020 Jul;92(7):786-790. doi: 10.1002/jmv.25918. Epub 2020 Apr 29.

引用本文的文献

1
Downregulation of sCD40 and sCTLA4 in Recovered COVID-19 Patients with Comorbidities.合并症康复期COVID-19患者中可溶性CD40和可溶性细胞毒性T淋巴细胞相关抗原4的下调
Pathogens. 2022 Sep 30;11(10):1128. doi: 10.3390/pathogens11101128.
2
SARS-CoV-2: lessons from both the history of medicine and from the biological behavior of other well-known viruses.SARS-CoV-2:从医学史和其他知名病毒的生物学行为中吸取的教训。
Future Microbiol. 2021 Sep;16(14):1105-1133. doi: 10.2217/fmb-2021-0064. Epub 2021 Sep 1.
3
Viral RNA in City Wastewater as a Key Indicator of COVID-19 Recrudescence and Containment Measures Effectiveness.城市废水中的病毒RNA作为新冠病毒复发和防控措施有效性的关键指标
Front Microbiol. 2021 May 17;12:664477. doi: 10.3389/fmicb.2021.664477. eCollection 2021.

本文引用的文献

1
Covid-19: The inside story of the RECOVERY trial.新冠疫情:“康复”试验的内幕故事
BMJ. 2020 Jul 8;370:m2670. doi: 10.1136/bmj.m2670.
2
Estimation of Excess Deaths Associated With the COVID-19 Pandemic in the United States, March to May 2020.估算 2020 年 3 月至 5 月美国 COVID-19 大流行期间的超额死亡人数。
JAMA Intern Med. 2020 Oct 1;180(10):1336-1344. doi: 10.1001/jamainternmed.2020.3391.
3
SARS coronavirus 2; how many more examples do we need before the world commits to decisive action?严重急性呼吸综合征冠状病毒2;在全世界承诺采取果断行动之前,我们还需要多少实例?
Rev Med Virol. 2020 May;30(3):e2110. doi: 10.1002/rmv.2110.
4
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.干扰素 beta-1b、洛匹那韦利托那韦和利巴韦林三联治疗住院 COVID-19 患者:一项开放标签、随机、2 期试验。
Lancet. 2020 May 30;395(10238):1695-1704. doi: 10.1016/S0140-6736(20)31042-4. Epub 2020 May 10.
5
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.新型冠状病毒病中“细胞因子风暴”的发病机制与治疗。
J Infect. 2020 Jun;80(6):607-613. doi: 10.1016/j.jinf.2020.03.037. Epub 2020 Apr 10.
6
Level of underreporting including underdiagnosis before the first peak of COVID-19 in various countries: Preliminary retrospective results based on wavelets and deterministic modeling.各国在新冠疫情首次高峰之前包括漏诊在内的漏报水平:基于小波和确定性建模的初步回顾性结果。
Infect Control Hosp Epidemiol. 2020 Jul;41(7):857-859. doi: 10.1017/ice.2020.116. Epub 2020 Apr 9.
7
Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling upon Coronavirus Replication.鉴定感染人类冠状病毒的细胞的脂质组特征:对冠状病毒复制时脂质代谢重编程的影响。
Viruses. 2019 Jan 16;11(1):73. doi: 10.3390/v11010073.
8
From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses.从 SARS 到 MERS:高致病性人冠状病毒研究的 10 年。
Antiviral Res. 2013 Oct;100(1):286-95. doi: 10.1016/j.antiviral.2013.08.015. Epub 2013 Sep 6.
9
Clinical management and infection control of SARS: lessons learned.严重急性呼吸综合征的临床管理和感染控制:经验教训。
Antiviral Res. 2013 Nov;100(2):407-19. doi: 10.1016/j.antiviral.2013.08.016. Epub 2013 Aug 28.
10
Development of antiviral therapy for severe acute respiratory syndrome.严重急性呼吸综合征抗病毒治疗的进展
Antiviral Res. 2005 Jun;66(2-3):81-97. doi: 10.1016/j.antiviral.2005.03.002. Epub 2005 Apr 26.

SARS-CoV:吸取的教训;错失的针对 SARS-CoV-2 的机会。

SARS-CoV: Lessons learned; opportunities missed for SARS-CoV-2.

机构信息

Institute of Interdisciplinary Research, University of Coimbra, Portugal.

出版信息

Rev Med Virol. 2021 Jan;31(1):1-6. doi: 10.1002/rmv.2152. Epub 2020 Aug 18.

DOI:10.1002/rmv.2152
PMID:32808446
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7460959/
Abstract

SARS-CoV-2 and Covid-19 have made a retrospective analysis of other coronavirus diseases important, so this article reviews the history of the SARS-CoV viral disease from 2003. Standard and clinical chemistry diagnostics were developed in response to the outbreak. The response to SARS is examined to determine if there were lessons learned before it disappeared in June and July 2003. Various diagnostic approaches were developed and implemented to assist in the rapid identification of patients and treatment of their illness, yet many of the approaches required days or weeks from the onset of fever to show statistical significance. Most of the therapeutic methods used during the outbreak relied on treating symptoms of the underlying illness, such as lower respiratory infections and systemic infection, rather than effectively suppressing or curtailing replication of the virus. Retrospective studies are examined to determine how the SARS outbreak was viewed 10 years on and what the authors hoped would be instructive patterns for possible future pandemics. Implementation of some of these recommendations might have helped ease the current pandemic but were overlooked for budgetary reasons that seem short-sighted at present.

摘要

SARS-CoV-2 和 COVID-19 使得对其他冠状病毒疾病进行回顾性分析变得很重要,因此本文回顾了 2003 年 SARS-CoV 病毒疾病的历史。针对此次疫情开发了标准和临床化学诊断方法。检查对 SARS 的反应,以确定在 2003 年 6 月和 7 月消失之前是否吸取了教训。开发并实施了各种诊断方法以帮助快速识别患者并治疗其疾病,但许多方法需要从发烧开始数天或数周后才能显示出统计学意义。在疫情爆发期间使用的大多数治疗方法都依赖于治疗潜在疾病的症状,例如下呼吸道感染和全身感染,而不是有效抑制或阻断病毒的复制。本文回顾了回顾性研究,以确定 SARS 爆发 10 年后的情况,以及作者希望为可能的未来大流行提供哪些有指导意义的模式。实施其中一些建议可能有助于缓解当前的大流行,但由于预算原因而被忽视,目前看来这些原因是目光短浅的。